Pohlman, Sandra M. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Pohlman, Sandra M.

Patent Number:
Title:
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-Vegf
Opposition Date:
Apr 30, 2024
Patent Number:
Title:
Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription
Opposition Date:
Apr 26, 2024
Patent Number:
Title:
Aav-Mediated Gene Therapy Restoring The Otoferlin Gene
Opposition Date:
Apr 19, 2024
Patent Number:
Title:
Composition For Cleaving A Target Dna Comprising A Guide Rna Specific For The Target Dna And Cas Protein-Encoding Nucleic Acid Or Cas Protein, And Use Thereof
Opposition Date:
Mar 1, 2023
Patent Number:
Title:
Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer
Opposition Date:
Jul 26, 2022
Patent Number:
Title:
Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer
Opposition Date:
May 31, 2022
Patent Number:
Title:
Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof
Applicant:
Opposition Date:
Mar 22, 2022
Patent Number:
Title:
Treatment Of Pd-L1-Positive Melanoma Using An Anti-Pd-1 Antibody
Opposition Date:
Dec 10, 2021
Patent Number:
Title:
Process For Cultivation Of Cho Cells
Applicant:
Opposition Date:
Nov 24, 2021
Patent Number:
Title:
Pharmaceutical Composition For Cancer Treatment
Opposition Date:
Nov 17, 2021

Want to track Pohlman, Sandra M.?

Feel free to send us a message here and we will get back to you